Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026)

Protalix BioTherapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 79.15% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $16.4 million (down 28.44% YoY), while the FY2025 annual figure was $21.0 million, up 18.38% from the prior year.
• Operating Expenses was $1.3 million for Q1 2026 at Protalix BioTherapeutics, down from $2.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $11.9 million in Q1 2022 to a low of $1.3 million in Q1 2026.
• Historically, Operating Expenses has averaged $7.0 million across 5 years, with a median of $7.4 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses surged 38.57% in 2025, then tumbled 79.15% in 2026.
• A 5-year view of Operating Expenses shows it stood at $8.7 million in 2022, then fell by 16.87% to $7.2 million in 2023, then plunged by 73.8% to $1.9 million in 2024, then surged by 38.57% to $2.6 million in 2025, then slumped by 52.28% to $1.3 million in 2026.
• The last three Operating Expenses figures came in at $1.3 million (Q1 2026), $2.6 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.